Lithium is used extensively in the control of manic-depressive illness despite the fact that its mode of action is still unknown. Many of the drugs that induce or reverse this illness interfere with the physiology of biogenic amines, suggesting that the changes in mood associated with depression or mania may be associated with alterations in amine neurotransmission (Schou, 1976) . A major challenge in this field is to identify the biochemical target for the action of lithium.
1. The effect of Li+ on the agonist-dependent metabolism of [3H]inositol has been studied in rat brain, rat parotid and the insect salivary gland. 2. When brain or parotid slices were incubated in the presence of [3H] inositol, Li+ was found to amplify the ability of agonists such as carbachol, phenylephrine, histamine, 5-hydroxytryptamine and Substance P to elevate the amount of label appearing in the inositol phosphates. 3. A different approach was used with the insect salivary gland, which was prelabelled with [3Hlinositol. After washing out the label, the subsequent release of 13Hlinositol induced by 5-hydroxytryptamine was greatly decreased by Li+. During Li+ treatment there was a large accumulation of [3Hlinositol 1-phosphate. 4 . This ability of Li+ to greatly amplify the agonist-dependent accumulation of myo-inositol 1-phosphate offers a novel technique for identifying those receptors that function by hydrolysing phosphatidylinositol. 5 . The therapeutic action of Li+ may be explained by this inhibition of myo-inositol 1-phosphatase, which lowers the level of myo-inositol and could lead to a decrease in the concentration of phosphatidylinositol, especially in those neurons that are being stimulated excessively. This alteration in phosphatidylinositol metabolism may serve to reset the sensitivity of those multifunctional receptors that generate second messengers such as Ca2 , cyclic GMP and the prostaglandins.
Lithium is used extensively in the control of manic-depressive illness despite the fact that its mode of action is still unknown. Many of the drugs that induce or reverse this illness interfere with the physiology of biogenic amines, suggesting that the changes in mood associated with depression or mania may be associated with alterations in amine neurotransmission (Schou, 1976) . A major challenge in this field is to identify the biochemical target for the action of lithium.
A potential breakthrough was made by Allison & Stewart (1971) when they discovered that Li+ decreased the concentration of myo-inositol in the cerebral cortex of rats. Further studies revealed that this Li+-induced decrease in myo-inositol was associated with very large elevations in the concentration of myo-inositol 1-phosphate resulting from an inhibition of the enzyme myo-inositol 1-phosphatase Allison, 1978; Sherman et al., 1981) . On the basis of these observations it has been suggested that Li+ may exert its therapeutic action by interfering with the metabolism of the phosphoinositides, which are known to play an important role in synaptic function (Sherman et al., 1981) .
The hydrolysis of phosphatidylinositol is an integral part of those receptors (e.g. muscarinic, H,-histaminergic, a1-adrenergic and V -vasopressin receptors) that function through Ca2+ (Michell, 1975 (Michell, , 1979 Berridge, 1980 Berridge, , 1981 Putney, 1981) . These receptors are multifunctional in that they may also be responsible for generating cyclic GMP and for releasing arachidonic acid (Berridge, 1981) . Li+ may thus exert its therapeutic action by altering the activity of this important class of receptors. Since these receptors have been examined more extensively in peripheral tissues, we decided to see whether Li+ exerted a similar effect on inositol metabolism in the brain and in both insect and mammalian salivary glands. The results reported in the present paper not only provide new insights into the therapeutic action of Li+ but they also suggest that Li+ can be used to provide a sensitive method for identifying the important class of receptors that function through Ca2+ rather than through cyclic AMP.
Methods

Incubation conditions
Salivary glands were isolated from adult female blowflies (Calliphora erythrocephala). The technique used to measure the release of [3Hlinositol from prelabelled glands was identical with that described by Fain & Berridge (1979) . The dissection and preparation of rat parotidgland fragments have been described previously (Hanley et al., 1980 The resin was allowed to settle and the supernatant was discarded. After washing the resin four times each with 2.5 ml of 5 mM-myo-inositol, inositol phosphates were eluted with 0.5 ml of 1 M-ammonium formate/0. 1 M-formic acid. Of this eluate, 0.4 ml was then removed and radioactivity was determined by scintillation counting.
Chromatographic separation of water-soluble inositol phosphates
Water-soluble extracts prepared as described above were applied to Whatman no. 1 chromatographic paper, which was subjected to high-voltage ionophoresis in a 0.1 M-ammonium carbamate/ ammonium acetate buffer, pH 9.0 (Clarke & Dawson, 1981) . After the paper had been dried at 700C each track was divided into lcm segments, which were treated overnight with 1 ml of water. After separation into two equal parts, one part was used to identify the position of label in the inositol phosphates, whereas the remaining portions were digested in HCl04 and their phosphorus contents were determined by the procedure of Bartlett (1959) to identify the position of standard myo-inositol 1-phosphate.
Water-soluble extracts were also applied to columns containing 1 ml of Dowex-1 (X8; Sigma Chemical Co., London S.W.6, U.K.) in the formate form. The phosphate esters were then eluted by the stepwise addition of solutions containing increasing concentrations of formate. Glycerophosphoinositol and inositol 1:2-cyclic phosphate were eluted with 5 mM-sodium tetraborate plus 60mM-sodium formate, whereas myo-inositol 1-phosphate was eluted with 5mM-sodium tetraborate plus 150mM sodium formate (Richards et al., 1979) . The penultimate solution contained 0.1M-formic acid plus 0.3M-ammonium formate, followed by 0.1 M-formic acid plus 0.75M-ammonium formate, each of which removes more polar inositol phosphates . The 1ml fractions eluted from the columns were counted for radioactivity after addition of lOml of Biofluor.
Results
The inhibitory effect of Li+ on myo-inositol 1-phosphatase will lead to the accumulation of myo-inositol 1-phosphate with a corresponding decline in the concentration of myo-inositol. Such changes in the level of these water-soluble components have been studied on a number of tissues using different techniques. Preliminary experiments were designed to detect the accumulation of inositol phosphates by measuring these labelled compounds in the water-soluble fraction obtained from brain and parotid during stimulation with various agonists. The ability of Li+ to decrease the release of [3Hlinositol from the insect salivary gland was used to illustrate how this ion can lower the intracellular concentration of myo-inositol. These indirect studies were supported by direct measurements of the effect of Li+ on the intracellular concentration of myoinositol 1-phosphate
The effect of Li+ on the labelling of inositol phosphates in cerebral cortex and parotid gland When slices of cerebral cortex were incubated in PHlinositol there was a gradual linear accumulation of label in the inositol phosphates (Fig. 1 ). The addition of either carbachol or Li+ caused a slight increase in the labelling but when added together there was a very large effect ( Fig. 1 ). There appeared to be a short latency, but after 10min the radioactivity in the inositol phosphates increased linearly over the 60min incubation period. This ability of carbachol to enhance the labelling of inositol phosphates was inhibited by atropine (Table 1) receptors, muscarinic acetylcholine receptors and receptors for the undecapeptide, Substance P. Only the a,-, muscarinic and Substance P receptors are coupled to inositol phospholipid breakdown. When added by themselves carbachol and phenylephrine had the largest effect, whereas that of Substance P was very small and isoprenaline was without effect (Table 2 ). Li+ by itself was slightly stimulatory, but, when added in combination with some of the agonists, it greatly enhanced the incorporation of label into the inositol phosphates. The greatest potentiation was seen with carbachol, whereas the effects with phenylephrine and Substance P were somewhat smaller.
The effect ofLi+ on inositol release from Calliphora salivary glands When isolated salivary glands are incubated with [3Hlinositol for 2h and then washed extensively, more than 95% of the label retained by the tissue is in the form of [3Hlphosphatidylinositol (Fain & Berridge, 1979) . The release of [3Hlinositol from such prelabelled glands is very small in control medium but is greatly increased by the addition of 0.5,uM-5-hydroxytryptamine (Fig. 2) . The enhanced release of [3Hlinositol observed during the action of 5-hydroxytryptamine is markedly decreased by treatment with 5mM-Li+ (Fig. 2) . This inhibitory effect on inositol release is consistent with the hypothesis that Li+ acts by blocking the enzyme that converts myo-inositol 1-phosphate into inositol. Another consequence of inhibiting this enzyme is that myo-inositol 1-phosphate will accumulate within the cell. When Li+ is withdrawn, the accumulated myo-inositol 1-phosphate will be converted into myo-inositol, which probably accounts for the pronounced compensatory release of PHlinositol during recovery from the Li+ treatment in Fig. 2 .
Effect ofvarying Li+ concentration
The serum and brain levels over which lithium exerts its therapeutic action in controlling manicdepressive illness are rather narrow (0.8-1.2 mM) (Ehrlich & Diamond, 1980) . It was of considerable interest, therefore, to determine the dose-response relationships for Li+ for the receptor-mediated events described above. The effect of various Li+ concentrations on the ability of carbachol to stimulate the accumulation of label in cerebral cortex and parotid was remarkably similar to its effect on the release of inositol from the insect salivary gland stimulated by 5-hydroxytryptamine (Fig. 3) . Li+ was half-maximally effective at about 1 mm, which lies within the normal therapeutic range (0.8-1.2mM) for serum concentrations of this drug. Since the intracellular level of Li+ in most cells is usually somewhat higher than those in serum (Ehrlich & Diamond, 1980) , the dose-response curves in Fig. 3 are in keeping with the previous observation that about 0.7 mM-Li+ half-maximally inhibited myo-inositol 1-phosphatase in vitro (Sherman et al., 1981) .
The accumulation of myo-inositol 1-phosphate during the action ofLi+ If Li+ acts by inhibiting the myo-inositol 1-phosphatase it should lead to the accumulation of myo-inositol 1-phosphate. The latter has been identified by using a combination of high-voltage ionophoresis and anion-exchange chromatography. The water-soluble fraction obtained after stimulating the insect salivary gland for 5 min with 5-hydroxytryptamine (0.5 uM) in the presenc¢ of 5mM-Li+ was mixed with a sample of tnyo-inovsitol 1-phosphate and subjected to high-vc$ltage ipno- Clarke & Dawson (1981) . The radioactivity that was located at this position was extracted from the paper and was found to be eluted from the anion-exchange columns at the same ionic strength as that used by Richards et al. (1979) . These anion-exchange columns were then used to measure the accumulation of myo-inositol 1-phosphate in the insect salivary gland during stimulation with 5-hydroxytryptamine either in the presence or absence of Li+. The ability of these anion-exchange columns to separate myo-inositol 1-phosphate from the remaining inositol phosphates is shown in Fig. 4 . As expected, Li+ suppressed the formation of free inositol that appears in the first peak. It had no effect on the level of the second peak, which is likely to be glycerophosphoinositol. The most pronounced effect of Li+ was found in the third region, which corresponds to myo-inositol 1-phosphate as described above. Experiments with the rat parotid gland and brain slice preparations (results not shown) gave remarkably similar results to those described for the insect salivary gland. Concomitant with carbachol stimulation, Li+ greatly enhanced the size of the myo-inositol 1-phosphate peak eluted from Dowex-1 columns. The remaining two peaks have not been identified. Li+ was found to slightly enhance the labelling of peak IV, but had no effect on peak V. The time course for the changes in accumulation of [3Hlinositol and [3Hlinositol 1-phosphate is shown in Fig. 5 . In the absence of 5-hydroxytryptamine, Li+ caused no change in the accumulation of [3Hlinositol (Fig. 5a ) and a very small accumulation of [3Hlinositol 1-phosphate (Fig. 5b,   inset ). In the absence of Li+, 5-hydroxytryptamine stimulated a small increase in the concentration of [3Hlinositol 1-phosphate (Fig. 5b) and a very large accumulation of [3Hlinositol (Fig. 5a ), most of which was probably released to the bathing medium. When glands were treated with a combination of Li+ and 5-hydroxytryptamine, the accumulation of [3Hlinositol was markedly suppressed (Fig. 5a ), whereas the concentration of [3H]inositol 1-phosphate rose to very high levels (Fig. 5b) . The dose-response curve for the effect of 5-hydroxytryptamine on the accumulation of 13H]-myo-inositol 1-phosphate in the insect salivary gland provides further evidence for the ability of Li+ to amplify agonist-dependent responses (Fig. 6 ). In the absence of Li+, the accumulation of this phosphate is small and barely detectable below a dose of l0nM, even though this level of 5-hydroxytryptamine can induce a maximal secretory response (Berridge, 1970) . In the presence of Li+, however, the accumulation of this phosphate is very much larger, especially at the higher concentrations of 5-hydroxytryptamine (Fig. 6) . The divergence of the two curves as the 5-hydroxytryptamine concentration increases indicates that Li+-induced myoinositol 1-phosphate accumulation is largely dependent on receptor-mediated turnover of inositol phospholipids. Li+ exerts a profound alteration in inositol metabolism by inhibiting the conversion of myoinositol 1-phosphate into myo-inositol by the enzyme myo-inositol I-phosphatase (Naccarato et al., 1974; . Inhibition of this enzyme will lower the concentration of myo-inositol, as has been reported in cerebral cortex during treatment with Li+ (Allison & Stewart, 1971; Allison et al., 1980) . Li+ also decreases the concentration of inositol in the hypothalamus, hippocampus and caudate nucleus , Allison, 1978 . Another consequence of inhibiting the phosphatase would be to elevate the intracellular level of myo-inositol 1-phosphate and such an effect has also been described in the cerebral cortex Allison, 1978; Sherman 1982 592 E 6. ., 1-et al., 1981) and has been confirmed for the parotid and insect salivary gland in the present study. By inhibiting the phosphatase, therefore, Li+ not only lowers the concentration of myo-inositol but also induces a large accumulation of myo-inositol 1-phosphate. The large amount of myo-inositol 1-phosphate that accumulates during the action of Li+ originates from two main sources (Fig. 7) . It can be synthesized de novo from glucose, leading to the formation of the L-enantiomer, or it can be released by phospholipase C activity from either phosphatidylinositol or the polyphosphoinositides in the form of the D-enantiomer. The fact that these two sources of inositol lead to the formation of separate enantiomers has enabled Sherman et al. (1981) to determine that 90% of the myo-inositol 1-phosphate that accumulates in the cerebral cortex during the action of Li+ is the D-enantiomer. This preponderance of the D-over the L-enantiomer demonstrates that most of the myo-inositol 1-phosphate that accumulates with chronic Li+ treatment comes from the breakdown of the inositol phospholipids (Sherman et al., 1981) . In our studies, however, PHiinositol-labelled myo-inositol 1-phosphate can only arise after phospholipase C attack on inositol phospholipids.
Specificity of Li+
This association between Li+ inhibition and phospholipid metabolism is intriguing because the phosphoinositides play an important role in those receptors that act through Ca2+ as a second messenger (Michell, 1975 (Michell, , 1979 Berridge, 1980 Berridge, , 1981 Putney, 1981) . Such receptor mechanisms may also be responsible for generating other important intracellular signals such as cyclic GMP and metabolites of arachidonic acid such as the prostaglandins, thromboxanes and the leukotrienes (Berridge, 1981) . Since there is some uncertainty at present whether the primary action of agonists is to stimulate the hydrolysis of phosphatidylinositol or the polyphosphoinositides , both possibilities have been included in Fig. 7 . For the present argument, it makes little difference which phospholipid is degraded because all the pathways lead to the formation of D-myo-inositol 1-phosphate (Fig. 7) . Our results clearly show that myo-inositol 1-phosphate accumulates only slowly in unstimulated cells, but its production accelerates dramatically on activation of receptor mechanisms responsible for hydrolysing inositol phospholipids. The ability of Li+ to raise the concentration of this phosphate in cerebral cortex in vivo could be explained by the endogenous activity of muscarinic receptors, since the effect is abolished by atropine Allison, 1978) . Similarly, endogenous stimulation of phosphatidylinositol turnover in cerebral cortex is inhibited by atropine (Friedel & Schanberg, 1972) . Only a small proportion of the blowfly salivary gland 5-hydroxytryptamine receptors need to be activated to evoke a maximal secretory response (Fain & Berridge, 1979) . Thus, 5-hydroxytryptamine stimulates secretion in the concentration range 1-10nM, which produces a relatively small phosphatidylinositol response (Fain & Berridge, 1979) . The 5-hydroxytryptamine-dependent hydrolysis of phosphatidylinositol more accurately reflects receptor occupation since it continues to be stimulated at agonist concentrations far in excess of 10nM. As expected, 5-hydroxytryptamine-stimulated myo-inositol 1-phosphate accumulation in the presence of Li+ requires relatively large concentrations of the agonist (Fig. 6 ). It therefore seems that accumulation of myo-inositol 1-phosphate in the presence of Li+ is proportional to the agonistdependent turnover of phosphatidylinositol. This observation may be of fundamental importance not only for providing an explanation for the therapeutic action of Li+ in controlling manic-depressive illness, but also for introducing a novel and sensitive technique for monitoring the activity of calciummobilising receptors. In effect Li+ can be used to potentiate agonist action in much the same way as the methylxanthines are used to augment the action of those receptors that act through cyclic AMP. The analogy must not be extended too far because, although cyclic AMP clearly functions as a second messenger, there is no evidence so far that myoinositol 1-phosphate performs any role as an intracellular signal.
Despite the fact that Li+ is used extensively in the control of manic-depressive illness, little is known about its therapeutic mode of action. There is growing evidence that the behavioural symptoms associated with manic-depressive illness may result from changes in the receptor mechanisms operating in various dopaminergic and serotoninergic pathways (Aprison et al., 1978; Treiser & Kellar, 1979; Nagayama et al., 1981; Staunton et al., 1982) . If the receptor mechanisms operating in these pathways employ the phosphoinositides, Li+ might exert its therapeutic action by interfering with the metabolism of these phospholipids (Sherman et al., 198 1) . The observations reported in this paper support this idea and provide further insights into the possible mode of action of Li+ within the central nervous system. Perhaps the most important point to emerge from this study is that the ability of Li+ to distort inositol metabolism is related to receptormediated turnover of inositol phospholipid head groups. In a quiescent cell, or when the cell is stimulated at normal agonist concentrations where turnover is low, there is very little accumulation of myo-inositol 1-phosphate, but this accumulates rapidly with increasing receptor occupancy (Fig. 6) . This implies that the action of Li+ in vivo may be rather selective in that it will be maximally effective against those cells whose inositol phospholipidlinked receptors are being abnormally stimulated. Thus, Li+ could preferentially affect those receptor pathways that are abnormally active and this may account for its equal effectiveness in controlling both mania and depression.
The next problem to consider is whether Li+ can bring about an alteration of receptor activity through its inhibitory effect on the myo-inositol 1-phosphatase. Inhibition of this enzyme does not cause any immediate effect on receptor action because the accumulation of inositol phosphate was found to increase linearly in the cerebral cortex for at least 60min (Fig. 1) . Similarly, Li+ had no effect on the ability of noradrenaline to stimulate smooth-muscle contraction (Beaty et al., 1981) . The fact that Li+ does not exert an immediate inhibitory effect on these receptor mechanisms is entirely consistent with the clinical observation that several days of chronic treatment are required for its effect (Bunney & Murphy, 1976) . The question to consider, therefore, is why such chronic stimulation should lead to a change in receptor activity. As described above, Li+ inhibits the conversion of myo-inositol 1-phosphate into inositol, which is the precursor for the synthesis of phosphatidylinositol (Fig. 7) . Our results indicate that Li+ will be most effective at lowering myoinositol concentration in those cells where receptor-linked inositol phospholipid breakdown is particularly active. It is in these same cells where the demand for myo-inositol for resynthesis of phosphatidylinositol to maintain receptor function will be greatest. Continued stimulation of such cells in the presence of Li+ may gradually deplete the membrane content of phosphatidylinositol and this in turn could decrease the sensitivity of those receptor mechanisms in which inositol phospholipids are important components of the transducing mechanism. Preliminary experiments do indeed suggest that prolonged treatment of parotid glands with carbachol in the presence of Li+ leads to substantial depletion of the phosphatidylinositol pool. Such a reduction in phospholipid leading to a decline in receptor sensitivity may account for the therapeutic action of Li+, especially since there are suggestions that one cause of depression may be an increase in the sensitivity of 5-hydroxytryptamine receptors (Aprison et al., 1978) .
A natural extension of this hypothesis is that manic-depressive illness is caused by an alteration in Ca2+-mobilizing receptors rather than in those operating through cyclic AMP. Staunton et al. (1982) have suggested that Li+ may also act on presynaptic dopamine autoreceptors for which there is no identified second messenger. The hypothesis developed above would suggest that these autoreceptors may act through the hydrolysis of phosphatidylinositol.
Many receptors in the periphery (e.g. muscarinic receptors on smooth muscle, pancreas and salivary glands) also hydrolyse phosphatidylinositol as part of their receptor mechanisms and should also be affected by Li+. However, these peripheral tissues seem to be relatively immune to the inhibitory effect of Li+. One explanation for this immunity might depend on the fact that these peripheral tissues are protected from Li+-induced reduction in inositol by obtaining this precursor from the plasma. Indeed, during treatment with Li+ the plasma level of inositol rises (Allison & Stewart, 1971; Allison, 1978) .
which would help to protect peripheral tissues against the action of the drug. Since inositol cannot cross the blood/brain barrier (Margolis et al., 1971; Barkai, 1979 ) the brain is not so protected and must produce its own inositol using the Li+-sensitive pathways shown in Fig. 7 . Hence the brain may be more susceptible to the action of Li+. The periphery does not escape completely from the action of Li+, which can induce certain disorders such as polydipsia and hypercalcaemia. The latter is of particular interest, because Shen & Sherrard (1982) consider that the Li+-induced hypercalcaemia results from a resetting of the 'calciostat' such that it takes a higher level of serum Ca2+ to inhibit parathyrin secretion. We consider that Li+ may act in a similar manner within the central nervoss system. Since it interferes with the turnover of inositol and hence the synthesis of phosphatidylinositol, Li+ may act to reset the sensitivity of those multifunctional receptors that generate second messengers such as Ca'+, cyclic GMP and the prostaglandins.
